• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Addition Technology adds acquired products to Intacs line

Article

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

AlphaCor is a flexible, biointegratable, one-piece artificial cornea designed to replace scarred or diseased native cornea. The product is for patients who have had not responded favorably to multiple corneal transplants and for those patients for whom a donor graft is likely to fail.

AlphaSphere is a soft-biocompatible orbital implant that the company plans to launch later this year. The product is FDA approved for treatment of patients who have lost an eye due to disease or trauma.

Intacs is the only additive corneal implant approved by the FDA for both keratoconus and myopia.

In other news, Addition Technology announced a 55% increase in second quarter 2006 sales of its corneal implants compared with the same quarter the previous year and a 20% increase over the first quarter 2006.

The company has had 13 consecutive quarters of double-digit growth in the United States and international markets.

“With any new technology, the adoption rate builds based upon successful patient outcomes experienced by surgeons,” said William M. Flynn, president and CEO of Addition Technology. “Internationally, we have a strong, technically-oriented distributor network that continues to aggressively train and assist a broad group of corneal surgeons.”

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.